戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 c fosfomycin, rendering it ineffective as an antibacterial drug.
2 ure-based design of a potent, broad-spectrum antibacterial drug.
3 sents a highly attractive target for a novel antibacterial drug.
4 flavine (ACF) has been known for years as an antibacterial drug.
5  lead structure for the development of a new antibacterial drug.
6 d release of osteoinductive peptides with an antibacterial drug.
7 RSA that can serve as possible model for new antibacterial drug.
8  host cells and an attractive target for new antibacterial drugs.
9 ppealing target for the development of novel antibacterial drugs.
10 hyX is a potential target for development of antibacterial drugs.
11 f antitumor, antiviral, antitrypanosomal and antibacterial drugs.
12 in humans, gyrase is a successful target for antibacterial drugs.
13 sign for novel, selective YopH inhibitors as antibacterial drugs.
14  and examining this step as a target for new antibacterial drugs.
15 ify essential genes encoding new targets for antibacterial drugs.
16  (Topo IV) are cellular targets of quinolone antibacterial drugs.
17 tentially be used for the development of new antibacterial drugs.
18 ction and its interaction with the quinolone antibacterial drugs.
19 thase systems and is an important target for antibacterial drugs.
20  in the absence or presence of anticancer or antibacterial drugs.
21 promising targets for the development of new antibacterial drugs.
22 e a suitable target for developing selective antibacterial drugs.
23 (ACM), microbiology, and receipt of nonstudy antibacterial drugs.
24 roviding a basis for future development into antibacterial drugs.
25  urgently needed to preserve these important antibacterial drugs.
26  scaffold for the development of much-needed antibacterial drugs.
27 t infection-and risk of harm from overuse of antibacterial drugs.
28  substantially reward the development of new antibacterial drugs.
29 tivize companies to invest in developing new antibacterial drugs.
30  to be a promising target for broad-spectrum antibacterial drugs.
31 ure and evaluating the impact of concomitant antibacterial drugs.
32 ents to guide and perform quality studies of antibacterial drugs.
33 CV) on the pathways to a number of important antibacterial drugs.
34 -known and validated target in the design of antibacterial drugs.
35 stal binding pocket altering specificity for antibacterial drugs.
36 attractive, important targets for developing antibacterial drugs.
37  polymerase (RNAP) is a validated target for antibacterial drugs.
38 ported DNA segments and cleavage-stabilizing antibacterial drugs.
39 gest that it could be a potential target for antibacterial drugs.
40 topoisomerases could be developed into novel antibacterial drugs.
41 res against infections include antiviral and antibacterial drugs and administration of immunoglobulin
42 flux pump, which is able to extrude selected antibacterial drugs and biocides from the membrane, lowe
43 ition of general strategies to develop smart antibacterial drugs and devices based on nanosilver.
44 olymer synthesis, identified new targets for antibacterial drugs and informed synthetic biology appro
45 include compounds with untapped potential as antibacterial drugs, and in view of the ever-growing unm
46 ens is a valid target for the development of antibacterial drugs, and that the existing clinical agen
47 ty reactions associated with fidaxomicin, an antibacterial drug approved for the treatment of Clostri
48 ed by an increase in orphan drugs as well as antibacterial drugs approved under the GAIN act.
49    A critical question is whether enough new antibacterial drugs are being discovered and developed.
50 is a potential target for new antifungal and antibacterial drugs as the shikimate pathway is absent f
51 unexploited antibiotics as a source of novel antibacterial drug candidates.
52 ognized as a promising target to develop new antibacterial drugs, catalyzes two key reactions: acetyl
53 d the efficacy and safety of the combination antibacterial drug ceftolozane-tazobactam versus meropen
54 t requires that patients take large doses of antibacterial drug combinations for at least 6 months af
55 lian cells makes it an attractive target for antibacterial drug design.
56 and validates PDF as an excellent target for antibacterial drug design.
57 rial cells makes it an attractive target for antibacterial drug design.
58 ibitors and is therefore a viable target for antibacterial drug design.
59 nition and inhibition, with implications for antibacterial drug design.
60  in the donor site, provides a direction for antibacterial drugs design.
61           Tedizolid is a novel oxazolidinone antibacterial drug designed to provide enhanced activity
62 formation Initiative (CTTI) seeks to advance antibacterial drug development (ABDD) by streamlining cl
63                                              Antibacterial drug development activity rebounded substa
64                                              Antibacterial drug development activity rebounded substa
65 asked with exploring economic incentives for antibacterial drug development and providing recommendat
66 formation Initiative (CTTI) seeks to advance antibacterial drug development by streamlining HABP/VABP
67 VABP development programs and promote needed antibacterial drug development for patients with serious
68 derivatives have the potential to be used in antibacterial drug development in strains carrying the N
69                                              Antibacterial drug development programs initiated in the
70                                              Antibacterial drug development programs initiated in the
71                                              Antibacterial drug development suffers from a paucity of
72 bacteria represents a promising strategy for antibacterial drug development.
73 rial species and are established targets for antibacterial drug development.
74 biochemical tool for identifying targets for antibacterial drug development.
75 lycan, rendering it an attractive target for antibacterial drug development.
76 sadvantages of different pull incentives for antibacterial drug development.
77 eas of consensus for economic incentives for antibacterial drug development.
78 ial fatty-acid synthesis and is a target for antibacterial drug development.
79 s, and ensure patient safety while advancing antibacterial drug development.
80 identification of novel systems suitable for antibacterial drug development.
81  evaluation as potential starting points for antibacterial drug development.
82 nts a new, and as yet, untested paradigm for antibacterial drug development.
83              This problem is significant for antibacterial drugs, difficult for antivirals, and utter
84 ins (PVPs) would greatly aid facilitation of antibacterial drug discovery and development.
85 es, and opportunities in the natural product antibacterial drug discovery arena, and to emerging appl
86                                The demise of antibacterial drug discovery brings the spectre of untre
87              Emerging trends in the field of antibacterial drug discovery from plants are also discus
88 fatty acid synthesis (FASII) as a target for antibacterial drug discovery in Gram-positive organisms
89  application of modern chemical synthesis to antibacterial drug discovery must play a critical role i
90                       Faced with a wealth of antibacterial drug discovery targets as a result of bact
91 nce (MDR), which makes these pumps important antibacterial drug discovery targets.
92 nes, there is a lack of sustainable leads in antibacterial drug discovery to address increasing multi
93 itch-region inhibitors, and implications for antibacterial drug discovery.
94 yme A (CoA) biosynthesis and is a target for antibacterial drug discovery.
95  structures are a valuable resource to guide antibacterial drug discovery.
96  cellular targets are needed to reinvigorate antibacterial drug discovery.
97 ctures are also a valuable resource to guide antibacterial drug discovery.
98 c pathway, they are an attractive target for antibacterial drug discovery.
99  genomes, making it an attractive target for antibacterial drug discovery.
100  transduction as a multicomponent target for antibacterial drug discovery.
101 bacteria and suggests a molecular target for antibacterial drug discovery.
102 ough paleoproteome mining as a framework for antibacterial drug discovery.
103 crobe behavior analysis with applications in antibacterial drug discovery.
104 ng replication and are validated targets for antibacterial drug discovery.
105 mportantly, clomiphene represents a lead for antibacterial drug discovery.
106 esses many of the requisite properties of an antibacterial drug, displaying potent and selective bact
107 umber of clinically important anticancer and antibacterial drugs, e.g. quinolones.
108 cessitates the development of broad-spectrum antibacterial drugs effective against multi-drug resista
109 ABP symptoms, and not receiving any nonstudy antibacterial drug for current CABP episode.
110 d that has shown repurposing potential as an antibacterial drug for infections due to Gram-positive b
111 temic human use as well as oral non-systemic antibacterial drugs for Clostridium difficile infections
112                        The evaluation of new antibacterial drugs for efficacy in this population is i
113 international expert panel selected systemic antibacterial drugs for their potential to treat infecti
114 roidal anti-inflammatory and fluoroquinolone antibacterial drugs for transport appears to be present
115  molecules, which include protein toxins and antibacterial drugs, from the cell.
116 vity and show how ClpC1 overactivation by an antibacterial drug generates toxicity.
117 comprehensive distribution assessment for an antibacterial drug, GSK2485680, delivered as a liposomal
118        The potential of these antibiotics as antibacterial drugs has been enhanced by the elimination
119           Since the 1990s, the number of new antibacterial drugs has plummeted and the number of anti
120 cs agrees with the observation that marketed antibacterial drugs have a polar distribution, with a lo
121 acy in this population is important, as many antibacterial drugs have demonstrated limitations when s
122 mation has opened up many new strategies for antibacterial drug hunting.
123 ddress the AMR threat include new methods of antibacterial drug identification and strategies that ne
124         The extensive and unregulated use of antibacterial drugs in animal farms in Lebanon can lead
125 ed by one of the most widely used classes of antibacterial drugs in human clinical use today, beta-la
126                                       Eleven antibacterial drugs in late stage clinical development a
127  confirmation of the mode of action of novel antibacterial drugs in S. pneumoniae.
128 oving endpoints for registrational trials of antibacterial drugs, including health-related quality-of
129 % with median development times for approved antibacterial drugs increasing to 8.2 years.
130 , with median development times for approved antibacterial drugs increasing to 8.2 years.
131                           Many antitumor and antibacterial drugs inhibit DNA topoisomerases by trappi
132  are literally 'against life'--are typically antibacterial drugs, interfering with some structure or
133             The continued development of new antibacterial drugs is critical to meet patient and publ
134                           The paucity of new antibacterial drugs is evident, and the arsenal against
135                      Herein, the blockbuster antibacterial drug linezolid is synthesized from simple
136 njunction with conventional chemotherapeutic antibacterial drugs might result in faster or more certa
137 stewater resulting from the production of an antibacterial drug (nalidixic acid) was investigated emp
138              Structural modifications of the antibacterial drug nitrofurantoin were envisioned, emplo
139 mrE was screened for resistance to two major antibacterial drugs--norfloxacin, a fluoroquinolone, and
140 predictions concerning the lack of effective antibacterial drugs occur with increasing frequency.
141                  Efflux pumps that transport antibacterial drugs out of bacterial cells have broad sp
142 resistance and the lagged discovery of novel antibacterial drugs, phage therapy for pathogenic bacter
143                     A review of the clinical antibacterial drug pipeline was recently published, but
144 ng gaps in developing a robust and effective antibacterial drug pipeline, drawing insights from trend
145  aim is the creation of a sustainable global antibacterial drug research and development enterprise w
146 ctive mechanisms represent novel targets for antibacterial drug research.
147 from those of the RNAP inhibitor and current antibacterial drug rifampin (Rif).
148                                    Quinolone antibacterial drugs such as nalidixic acid target DNA gy
149            This enzyme, ThyX, is a potential antibacterial drug target, since humans and most eukaryo
150 nt in ligase evolution and favors LigA as an antibacterial drug target.
151  biosynthesis pathway and is a potential new antibacterial drug target.
152                                    Quinolone antibacterial drugs target both DNA gyrase (Gyr) and top
153 e important for the development of effective antibacterial drugs targeting RNase E.
154      Bacterial topoisomerases are attractive antibacterial drug targets because of their importance i
155 was developed to identify and prioritize the antibacterial drug targets in Clostridium botulinum (Clb
156  M. tuberculosis viability and are validated antibacterial drug targets, but the requirements for ass
157 es a promising approach to validation of new antibacterial drug targets.
158 cterial SBPs are of considerable interest as antibacterial drug targets.
159 gulation, riboswitches have been proposed as antibacterial drug targets.
160 y for the discovery of novel, yet unexplored antibacterial drug targets.
161 tate of DNA during replication and validated antibacterial drug targets.
162 flavin synthesis are considered as potential antibacterial drug targets.
163 for cell growth, and therefore may represent antibacterial drug targets.
164 f July 1, 2018, 30 new chemical entity (NCE) antibacterial drugs, ten biologics, ten NCEs against Myc
165 lication of this concept to the screening of antibacterial drugs that act at the major bacterial targ
166 modulate the effectiveness of many antitumor/antibacterial drugs that act by stabilizing cleavage-com
167                                        Novel antibacterial drugs that are effective against infection
168              There is an urgent need for new antibacterial drugs that are effective against infection
169 idly, requiring urgent identification of new antibacterial drugs that are effective against multidrug
170 se pathways may be promising targets for new antibacterial drugs that prevent bacteria dormancy.
171  demonstrates progress in development of new antibacterial drugs that target infections caused by res
172 nstrates some progress in development of new antibacterial drugs that target infections caused by res
173         Quinolones are potent broad spectrum antibacterial drugs that target the bacterial type II DN
174 esearch to facilitate the development of new antibacterial drug therapies for treatment of hospital-a
175  end-point failures were receipt of nonstudy antibacterial drug therapy and loss to follow-up.
176  endpoint failures were receipt of non-study antibacterial drug therapy and loss to follow-up.
177                         Concomitant nonstudy antibacterial drug therapy most commonly included beta-l
178 niae or Staphylococcus aureus, have received antibacterial drug therapy prior to randomization, and h
179 niae or Staphylococcus aureus, have received antibacterial drug therapy prior to randomization, and h
180  contexts of enrollment, endpoints, nonstudy antibacterial drug therapy, and antimicrobial resistance
181 lowest proportion of participants with prior antibacterial drug therapy.
182 t for the discovery and development of novel antibacterial drugs to address the critical medical need
183 , which could guide the development of novel antibacterial drugs to combat infections with multidrug-
184                                  Addition of antibacterial drugs to interim antibacterial cement spac
185                Diverse molecules, from small antibacterial drugs to large protein toxins, are exporte
186                                 To bring new antibacterial drugs to the market is challenging because
187 y (MODIFY) I/II trial participants receiving antibacterial drug treatment for CDI.
188  in MODIFY I/II trial participants receiving antibacterial drug treatment for CDI.
189                                          For antibacterial drug trials, understanding enrollment tren
190  encoded DHFRs that confer resistance to the antibacterial drug trimethoprim.
191 ently in response to the clinical use of the antibacterial drug trimethoprim.
192 chanism to the increased clinical use of the antibacterial drug trimethoprim.
193 zyme that confers clinical resistance to the antibacterial drug trimethoprim.
194  reductase (DHFR) provides resistance to the antibacterial drug trimethoprim.
195  be probed by an in vivo selection using the antibacterial drug, trimethoprim, where the water conten
196 enzyme in bacteria confers resistance to the antibacterial drug, trimethoprim.
197 ncoded enzyme that confers resistance to the antibacterial drug, trimethoprim.
198 w drug applications (INDs) for new, systemic antibacterial drugs under active development between 198
199 al admissions, attendant costs, and unneeded antibacterial drug use, much of which would otherwise be
200                      One hundred forty-eight antibacterial drugs were on shortage over the 13-year st
201 um tuberculosis response upon exposure to 18 antibacterial drugs where only one transcriptomic sample
202 esistance and development of narrow-spectrum antibacterial drugs, which is an urgent need for contemp
203  Therefore, modification of trimethoprim, an antibacterial drug with no tumor growth inhibition, led
204                       The development of new antibacterial drugs with different mechanisms of action
205                           The development of antibacterial drugs with new mechanisms of action is cru
206                                          New antibacterial drugs without pre-existing cross-resistanc

 
Page Top